Vertex Pharmaceuticals (VRTX) EBIAT (2009 - 2026)

Vertex Pharmaceuticals has reported EBIAT for 18 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, EBIAT rose 59.59% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (up 538.7% YoY), and the FY2025 full-year result was $4.0 billion, up 838.09% from the prior year.
• EBIAT for Q1 2026 stood at $1.0 billion, down from $1.2 billion in the prior quarter.
• The five-year high for EBIAT was $1.2 billion in Q4 2025, with the low at -$3.6 billion in Q2 2024.
• Average EBIAT over 5 years is $670.0 million, with a median of $930.5 million recorded in 2022.
• Year-over-year, EBIAT soared 1109.7% in 2022 and tumbled 492.44% in 2024.
• Tracing VRTX's EBIAT over 5 years: stood at $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then slipped by 5.76% to $913.0 million in 2024, then surged by 30.46% to $1.2 billion in 2025, then retreated by 13.41% to $1.0 billion in 2026.
• The last three EBIAT figures came in at $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison